NZ536739A - Immediate release pharmaceutical formulation - Google Patents

Immediate release pharmaceutical formulation

Info

Publication number
NZ536739A
NZ536739A NZ536739A NZ53673903A NZ536739A NZ 536739 A NZ536739 A NZ 536739A NZ 536739 A NZ536739 A NZ 536739A NZ 53673903 A NZ53673903 A NZ 53673903A NZ 536739 A NZ536739 A NZ 536739A
Authority
NZ
New Zealand
Prior art keywords
compound
formulation
pab
aze
acid
Prior art date
Application number
NZ536739A
Other languages
English (en)
Inventor
Tord Inghardt
Anders Magnusson
Carl-Gustaf Sigfridsson
Mikael Thune
Alami Susanna Abrahmsen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ536739(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to NZ549273A priority Critical patent/NZ549273A/en
Publication of NZ536739A publication Critical patent/NZ536739A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ536739A 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation NZ536739A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ549273A NZ549273A (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201658A SE0201658D0 (sv) 2002-05-31 2002-05-31 Immediate release pharmaceutical formulation
PCT/SE2003/000857 WO2003101423A1 (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
NZ536739A true NZ536739A (en) 2006-10-27

Family

ID=20288036

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ536739A NZ536739A (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation

Country Status (24)

Country Link
US (1) US20060014734A1 (ru)
EP (1) EP1513496A1 (ru)
JP (2) JP4537197B2 (ru)
KR (1) KR20050010016A (ru)
CN (1) CN1655760A (ru)
AR (1) AR039935A1 (ru)
AU (2) AU2003241239B2 (ru)
BR (1) BR0311363A (ru)
CA (1) CA2485533A1 (ru)
CL (1) CL2008003324A1 (ru)
IL (1) IL165069A0 (ru)
IS (1) IS7582A (ru)
MX (1) MXPA04011943A (ru)
NO (1) NO20044810L (ru)
NZ (1) NZ536739A (ru)
PL (1) PL373908A1 (ru)
RU (2) RU2351314C2 (ru)
SA (1) SA03240403B1 (ru)
SE (1) SE0201658D0 (ru)
SG (1) SG172473A1 (ru)
TW (2) TWI311555B (ru)
UA (1) UA82191C2 (ru)
WO (1) WO2003101423A1 (ru)
ZA (1) ZA200409237B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
EA200900571A1 (ru) * 2006-10-20 2009-12-30 Айкос Корпорейшн Композиции chk1 ингибиторов
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
US8977382B2 (en) * 2012-05-11 2015-03-10 D.P. Technology Corp. Automatic method for milling complex channel-shaped cavities
US9927801B2 (en) 2012-05-11 2018-03-27 D.P. Technology Corp. Automatic method for milling complex channel-shaped cavities via coupling flank-milling positions
CN102827053A (zh) * 2012-09-20 2012-12-19 天津嘉宏科技有限公司 芳族脒衍生物，其制备方法及作为药物的用途
MA40281B1 (fr) 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
JP6500092B2 (ja) 2014-09-15 2019-04-10 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｔ型カルシウムチャンネルブロッカーとしてのトリアゾール化合物
HRP20220463T1 (hr) 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252566A (en) * 1991-11-12 1993-10-12 Eli Lilly And Company Antithrombotic agents
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
AU3496297A (en) * 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
SE9704401D0 (sv) * 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
WO2000018352A2 (en) * 1998-09-28 2000-04-06 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
BR0007453A (pt) * 1999-01-13 2001-10-30 Astrazeneca Ab Composto, formulação farmacêutica, uso de umcomposto, método de tratamento de uma condiçãoonde a inibição da trombina é requerida e,processo de preparação de um composto
WO2002014270A1 (en) * 2000-08-16 2002-02-21 Astrazeneca Ab New amidino derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation

Also Published As

Publication number Publication date
AU2003241239A1 (en) 2003-12-19
IL165069A0 (en) 2005-12-18
TWI311555B (en) 2009-07-01
CA2485533A1 (en) 2003-12-11
TW200735864A (en) 2007-10-01
NO20044810L (no) 2005-02-24
RU2004133387A (ru) 2005-07-10
ZA200409237B (en) 2005-07-14
AU2003241239B2 (en) 2010-03-18
BR0311363A (pt) 2005-03-01
CN1655760A (zh) 2005-08-17
PL373908A1 (en) 2005-09-19
KR20050010016A (ko) 2005-01-26
CL2008003324A1 (es) 2009-03-06
SE0201658D0 (sv) 2002-05-31
JP4537197B2 (ja) 2010-09-01
TW200400940A (en) 2004-01-16
SG172473A1 (en) 2011-07-28
UA82191C2 (ru) 2008-03-25
US20060014734A1 (en) 2006-01-19
AU2010200821A1 (en) 2010-03-25
IS7582A (is) 2004-12-03
SA03240403B1 (ar) 2008-12-23
JP2005536471A (ja) 2005-12-02
WO2003101423A1 (en) 2003-12-11
RU2351314C2 (ru) 2009-04-10
AR039935A1 (es) 2005-03-09
JP2010209090A (ja) 2010-09-24
EP1513496A1 (en) 2005-03-16
MXPA04011943A (es) 2005-03-31
RU2008141850A (ru) 2010-04-27

Similar Documents

Publication Publication Date Title
AU2010200821A1 (en) Immediate release pharmaceutical formulation
TWI788702B (zh) {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
CA2485535C (en) Modified release pharmaceutical formulation
US20080269176A1 (en) New Salts
US7781424B2 (en) Modified release pharmaceutical formulation
US20170226119A1 (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
NZ549273A (en) Immediate release pharmaceutical formulation
NZ549176A (en) Modified release pharmaceutical formulation
JP2023533874A (ja) Ｐｎ６０４７の塩酸塩の多形体

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed